These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 88745)

  • 21. Chemotherapy of influenza and herpes virus infections.
    Oxford JS
    J R Coll Physicians Lond; 1981 Oct; 15(4):218-9, 222-6. PubMed ID: 6275080
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro sensitivity of macropodid herpesvirus 2 to selected anti-herpetic compounds.
    Smith G
    J Wildl Dis; 1996 Jan; 32(1):117-20. PubMed ID: 8627922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developmental aspects of selected antiviral chemotherapeutic agents.
    Whitley RJ; Alford CA
    Annu Rev Microbiol; 1978; 32():285-300. PubMed ID: 213011
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of alpha- and beta-D-arabinosyladenosine and beta-D-arabinosylthymine on the synthesis of HSV types 1- and 2-infected cells.
    Falke D; Moser H; Link D; Müller WE
    Adv Ophthalmol; 1979; 38():197-203. PubMed ID: 230716
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication.
    Sloan BJ; Kielty JK; Miller FA
    Ann N Y Acad Sci; 1977 Mar; 284():60-80. PubMed ID: 212990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iontophoretic application of adenine arabinoside monophosphate for the treatment of herpes simplex virus type 2 skin infections in hairless mice.
    Kwon BS; Hill JM; Wiggins C; Tuggle C
    J Infect Dis; 1979 Dec; 140(6):1014. PubMed ID: 94335
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapy of viral infections.
    Grieco MH
    Bull N Y Acad Med; 1982 Nov; 58(8):711-20. PubMed ID: 6301589
    [No Abstract]   [Full Text] [Related]  

  • 28. Advances in antiviral chemotherapy.
    King DH
    J Am Vet Med Assoc; 1984 Nov; 185(10):1115-7. PubMed ID: 6096322
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiviral agents: an update--Part I.
    Bogger-Goren S; Ogra PL
    Indian J Pediatr; 1980; 47(388):431-40. PubMed ID: 7014434
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.
    Weiss GB; Metch B; Von Hoff DD; Taylor SA; Saiers JH
    Cancer Treat Rep; 1987 Dec; 71(12):1313-4. PubMed ID: 2446753
    [No Abstract]   [Full Text] [Related]  

  • 31. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1990 Feb; 263(6):793. PubMed ID: 1688632
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis B-associated membranous glomerulonephritis treated with adenine arabinoside monophosphate.
    Esteban R; Buti M; Vallés M; Allende H; Guardia J
    Hepatology; 1986; 6(4):762-3. PubMed ID: 2426174
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II trial of fludarabine in patients with epithelial ovarian cancer.
    Kavanagh JJ; Stringer CA; Copeland LJ; Gershenson DM; Saul P
    Cancer Treat Rep; 1986 Mar; 70(3):425-6. PubMed ID: 2420446
    [No Abstract]   [Full Text] [Related]  

  • 34. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.
    Schaeffer HJ; Beauchamp L; de Miranda P; Elion GB; Bauer DJ; Collins P
    Nature; 1978 Apr; 272(5654):583-5. PubMed ID: 205792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Responses of patients to arabinosyladenine-5'-phosphate correlated with an in vitro test.
    Lepage GA; Khaliq A
    Adv Enzyme Regul; 1978; 17():437-54. PubMed ID: 93404
    [No Abstract]   [Full Text] [Related]  

  • 36. [Viruses and antiviral drug resistance].
    Hovi T; Järvinen A; Pyhälä R; Ristola M; Salminen M
    Duodecim; 2002; 118(9):911-8. PubMed ID: 12238169
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).
    Weller IV; Bassendine MF; Craxi A; Fowler MJ; Monjardino J; Thomas HC; Sherlock S
    Gut; 1982 Sep; 23(9):717-23. PubMed ID: 6179819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study.
    Harvey WH; Fleming TR; Von Hoff DD; Katterhagen JG; Coltman CA
    Cancer Treat Rep; 1987 Dec; 71(12):1319-20. PubMed ID: 2446754
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
    Weller IV
    J Hepatol; 1986; 3 Suppl 2():S107-10. PubMed ID: 2439568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
    Balducci L; Blumenstein B; Von Hoff DD; Davis M; Hynes HE; Bukowski RM; Crawford ED
    Cancer Treat Rep; 1987 May; 71(5):543-4. PubMed ID: 2436773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.